Allergan picks up option for Editas' rare eye disease drug; CureGenetics bags $17M
→ Allergan has stepped in to pick up its development option on Editas‘ experimental EDIT-101 for Leber congenital amaurosis type 10. And the smaller biotech is grabbing co-promotion rights as they look to a future expansion into commercial operations. Editas gets $15 million upfront with another $25 million due on the IND.
→ China gene-editing biotech CureGenetics has rounded up a $17 million round to back its development. Qiming Venture Partners led the round with additional investors which included CTS Capital and Ascendin Investment. The company plans to use the money on an IND and pipeline development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.